SCHEMBL24251875

SCHEMBL24251875

FC(F)(F)c1nc2cc(Br)ccc2o1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ELANE P08246 4/20 0.40
▸ XDH P47989 1/20 0.40
▸ MAPT P10636 4/20 0.39
▸ XBP1 P17861 1/20 0.39
▸ HIF1A Q16665 1/20 0.39
▸ NT5E P21589 1/20 0.39
▸ KDM4E B2RXH2 3/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ TP53 P04637 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ FBP1 P09467 1/20 0.37
▸ HDAC6 Q9UBN7 2/20 0.35
▸ POLB P06746 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ HDAC3 O15379 1/20 0.35
▸ HDAC1 Q13547 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30082485 1.00 ELANE (0.40) ELANEXDHMAPTXBP1HIF1A
SCHEMBL30524315 0.89 XDH (0.40) XDHMAPTXBP1HIF1ANT5E
SCHEMBL31372442 0.82 LMNA (0.43) ELANEXDHMAPTXBP1HIF1A
SCHEMBL12301096 0.79 ELANE (0.58) ELANEMAPTKDM4ENPC1RAB9A
SCHEMBL20502744 0.79 RAB9A (0.53) MAPTKDM4EMEN1KMT2ANPC1
SCHEMBL28602639 0.75 MAPT (0.47) XDHMAPTXBP1HIF1AKDM4E
SCHEMBL30011535 0.75 MAPT (0.47) XDHMAPTXBP1HIF1AKDM4E
SCHEMBL21935171 0.75 HSPD1 (0.41) ELANEMAPTKDM4EMEN1KMT2A
SCHEMBL30358390 0.75 GRK6 (0.41) XDHMAPTXBP1HIF1AKDM4E
SCHEMBL14243226 0.74 HDAC6 (0.63) MAPTKDM4EMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115485281-B FGFR and mutation inhibitor thereof, and preparation method and application thereof 上海和誉生物医药科技有限公司 2023-11-21 — — CN disclosed
US-20230303575-A1 FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-09-28 — — US disclosed
US-20230303575-A1 FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-09-28 — — US disclosed
EP-4169922-A1 FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2023-04-26 — — EP disclosed
CN-115485281-A FGFR and mutation inhibitor thereof, and preparation method and application thereof 上海和誉生物医药科技有限公司 2022-12-16 — — CN disclosed
WO-2022033532-A1 FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海和誉生物医药科技有限公司 2022-02-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303575-A1 FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF FGFR3, FGFR1, FGFR4 ELANE 4730/4885XDH 3240/4885MAPT 4068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback